281 related articles for article (PubMed ID: 15541815)
1. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
5. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
9. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
10. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
[TBL] [Abstract][Full Text] [Related]
12. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
Tomizawa Y; Nakajima T; Kohno T; Saito R; Yamaguchi N; Yokota J
Cancer Res; 1998 Dec; 58(23):5478-83. PubMed ID: 9850082
[TBL] [Abstract][Full Text] [Related]
14. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
[TBL] [Abstract][Full Text] [Related]
15. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
[TBL] [Abstract][Full Text] [Related]
16. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
[TBL] [Abstract][Full Text] [Related]
17. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
18. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
Yu ZH; Wang YC; Chen LB; Song Y; Liu C; Xia XY; Lin Q; Ma CY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):284-7. PubMed ID: 18788633
[TBL] [Abstract][Full Text] [Related]
20. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]